Pharvaris to Host Virtual R&D Call on Deucrictibant and Bradykinin-Mediated Angioedema on June 4, 2025

Pharvaris announces a virtual R&D call on June 4, discussing deucrictibant and bradykinin-mediated angioedema treatment advancements.

Quiver AI Summary

Pharvaris, a late-stage biopharmaceutical company based in Zug, Switzerland, has announced a virtual R&D call titled "Deucrictibant: Beyond HAE Type 1/2" scheduled for June 4, 2025. This event will focus on the pathophysiology, prevalence, and treatment of bradykinin-mediated diseases, particularly hereditary angioedema (HAE). Key topics will include the unmet medical needs for patients suffering from these conditions and how Pharvaris' drug, deucrictibant, has the potential to meet these needs. The event will feature presenters from both Pharvaris and Amsterdam UMC. Interested participants can register for the live webcast on the company's website, with a replay available afterwards. Pharvaris is advancing its development of oral bradykinin B2 receptor antagonists aimed at providing effective and well-tolerated treatments for bradykinin-mediated angioedema.

Potential Positives

Pharvaris is hosting a virtual R&D call to discuss the potential of their drug, deucrictibant, which could address unmet needs in the treatment of bradykinin-mediated angioedema.
The company has demonstrated positive data from Phase 2 studies, suggesting efficacy of deucrictibant for both prophylaxis and on-demand treatment of hereditary angioedema (HAE).
Pharvaris is actively advancing deucrictibant into pivotal Phase 3 studies, indicating progress in their drug development pipeline and a commitment to addressing significant patient needs.

Potential Negatives

The announcement of the virtual R&D call may indicate that the company is focusing on educational efforts rather than providing updates on product commercialization or financial performance, which could signal uncertainty about market readiness.
Despite the positive Phase 2 data, the ongoing Phase 3 studies for deucrictibant may raise concerns about the drug's efficacy and safety in a broader patient population, suggesting potential risks for future approvals.
There is no mention of specific timelines for the completion of the Phase 3 studies or expected regulatory filings, which could lead to uncertainty among investors and stakeholders regarding the company's progress and future prospects.

FAQ

What is the purpose of Pharvaris' upcoming virtual R&D call?

The call aims to discuss deucrictibant and address unmet needs in bradykinin-mediated angioedema treatments.

When will the R&D call on deucrictibant take place?

The virtual event is scheduled for June 4, 2025, at 8:00 a.m. ET/14:00 CET.

Who will be presenting at the Pharvaris R&D call?

Presenters include experts from Amsterdam UMC and Pharvaris’ leadership team, including M.D.s and a Chief Development Officer.

How can I register for the Pharvaris event?

Registration can be completed at the Pharvaris events page on their website: https://ir.pharvaris.com/news-events/events-presentations.

What therapeutic area does Pharvaris focus on?

Pharvaris is focused on developing treatments for bradykinin-mediated diseases, particularly hereditary angioedema.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$PHVS Hedge Fund Activity

We have seen 24 institutional investors add shares of $PHVS stock to their portfolio, and 20 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ECOR1 CAPITAL, LLC removed 900,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $17,253,000
SOLEUS CAPITAL MANAGEMENT, L.P. added 216,483 shares (+36.2%) to their portfolio in Q4 2024, for an estimated $4,149,979
FMR LLC added 189,714 shares (+3.6%) to their portfolio in Q4 2024, for an estimated $3,636,817
VR ADVISER, LLC removed 175,476 shares (-5.2%) from their portfolio in Q4 2024, for an estimated $3,363,874
OCTAGON CAPITAL ADVISORS LP added 157,530 shares (+25.4%) to their portfolio in Q4 2024, for an estimated $3,019,850
PRICE T ROWE ASSOCIATES INC /MD/ added 118,408 shares (+36.4%) to their portfolio in Q4 2024, for an estimated $2,269,881
NORTHERN TRUST CORP added 76,188 shares (+483.9%) to their portfolio in Q4 2024, for an estimated $1,460,523

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that it will host a virtual R&D call, titled “Deucrictibant: Beyond HAE Type 1/2” on Wednesday, June 4, at 8:00 a.m. ET/14:00 CET.

The virtual event will explore the pathophysiology and prevalence of bradykinin-mediated angioedema, the current treatment paradigm and unmet needs of those living with bradykinin-mediated angioedema, the potential of deucrictibant to address those unmet needs, and Pharvaris’ biomarker approach to identification of those living with bradykinin-mediated angioedema and other diseases.

Presenters of the event are:

Danny M. Cohn, M.D., Ph.D. , Department of Vascular Medicine, Amsterdam UMC (an accredited center of ACARE)
Anne Lesage, Ph.D. , Chief Early Development Officer, Pharvaris
Peng Lu, M.D., Ph.D. , Chief Medical Officer, Pharvaris
Berndt Modig , Chief Executive Officer, Pharvaris

To register for the live webcast, please visit https://ir.pharvaris.com/news-events/events-presentations in the News and Events section of the company’s website. Following the live webcast, an archived replay will be available for at least 30 days after the event.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/ .